CBIO
NASDAQ · Biotechnology
Crescent Biopharma Inc
$13.06
+0.12 (+0.93%)
Financial Highlights (FY 2026)
Revenue
38.32M
Net Income
-551,112,289
Gross Margin
-0.5%
Profit Margin
-1,438.1%
Rev Growth
+413.7%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | -0.5% | 44.8% | 44.8% | 44.8% |
| Operating Margin | -1,407.5% | 0.5% | 0.5% | 0.5% |
| Profit Margin | -1,438.1% | 0.3% | 0.4% | 0.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 38.32M | 57.99M | 51.60M | 54.22M |
| Gross Profit | -193,061 | 25.95M | 23.10M | 24.27M |
| Operating Income | -539,398,217 | 269.0K | 235.0K | 268.5K |
| Net Income | -551,112,289 | 180.8K | 210.8K | 183.8K |
| Gross Margin | -0.5% | 44.8% | 44.8% | 44.8% |
| Operating Margin | -1,407.5% | 0.5% | 0.5% | 0.5% |
| Profit Margin | -1,438.1% | 0.3% | 0.4% | 0.3% |
| Rev Growth | +413.7% | +8.6% | +24.1% | +21.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 58.46M | 55.07M | 55.38M |
| Total Equity | — | 113.09M | 116.97M | 133.63M |
| D/E Ratio | — | 0.52 | 0.47 | 0.41 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -539,118,307 | 390.2K | 358.0K | 370.7K |
| Free Cash Flow | — | 84.1K | 101.4K | 117.1K |